My NCBI Sign In
Jump to: Authorized Access | Attribution | Authorized Requests

Study Description

Sturge-Weber syndrome (SWS) is a rare, congenital syndrome with vascular malformations of the brain, skin and eye. The underlying cause of SWS is unknown and the extent of involvement varies greatly from patient to patient. Those with brain involvement present with seizures, stroke-like episodes and neurologic deficits, usually in infancy. Those with eye involvement frequently develop vision threatening glaucoma and retinal injury. Treatment has been largely symptomatic and hampered by delayed diagnosis and the rarity of the condition.

The purpose of this study is to determine the reliability of non-invasive measures to be developed as biomarkers for SWS and to determine inter-rater reliability where appropriate. This includes measuring reliability for:

  • Power asymmetry on Quantitative Electroencephalogram
  • Asymmetry of Transcranial Doppler velocity and pulsatility
  • Behavioral outcome measures (PEDI, Erhardt, Modified Rankin Scale)
  • Optical Coherence Tomography

Approximately 40 subjects will participate in this observational, cross-sectional study, and this current study release includes data of the first n=25 subjects.

Authorized Access
Publicly Available Data (Public ftp)

Connect to the public download site. The site contains release notes and manifests. If available, the site also contains data dictionaries, variable summaries, documents, and truncated analyses.

Study Inclusion/Exclusion Criteria
Inclusion Criteria:
  • Individuals with SWS and brain involvement (Aims 1-3): for the purposes of this study SWS brain involvement is defined as having shown on MRI imaging evidence of the typical vascular malformation which includes the following: leptomeningeal angioma, choroid plexus glomus, and associated venous angioma/malformation.
  • Individuals with SWS and eye involvement (Aim 4): for the purposes of this study SWS eye involvement is defined as individuals with a portwine birthmark in the V1 dermatomal distribution
  • Able (or parents able) to provide informed consent
  • Able to cooperate with tests
  • Age 6 months to 21 years (Aims 1-3 only)

Exclusion Criteria:
  • Subjects unable to cooperate with the studies will be excluded.
Study History

  • Study Activated March 22, 2011
  • Last Accrual October 10, 2012

Selected publications
Diseases/Traits Related to Study (MESH terms)
Links to Related Resources
Authorized Data Access Requests
Study Attribution